Annual report pursuant to Section 13 and 15(d)

Research and Development Agreements - Additional Information (Detail)

v3.24.1
Research and Development Agreements - Additional Information (Detail) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended 64 Months Ended
Feb. 28, 2021
Sep. 30, 2018
Mar. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Research And Development Collaboration Agreements [Line Items]            
Revenue from collaborative arrangement       $ 57,306 $ 19,754  
Deferred revenue, current       9,031 45,573 $ 9,031
Deferred revenue, non-current         5,904  
Grants revenue receivable       250   250
Research and development revenue            
Research And Development Collaboration Agreements [Line Items]            
Revenue from collaborative arrangement       52,625 19,754  
Bristol Myers Squibb Collaboration Agreement | License Agreement Terms [Member] | Bristol Myers Squibb            
Research And Development Collaboration Agreements [Line Items]            
Upfront payment $ 70,000          
Transaction price allocated to performance obligations 70,000          
Deferred revenue, current       9,000 45,300 9,000
Deferred revenue, non-current       0 5,900 0
Bristol Myers Squibb Collaboration Agreement | License Agreement Terms [Member] | Bristol Myers Squibb | Maximum            
Research And Development Collaboration Agreements [Line Items]            
Milestone payments receivable if option is exercised 874,500          
Additional milestone payments receivable if option is exercised $ 450,000          
Bristol Myers Squibb Collaboration Agreement | License Agreement Terms [Member] | Bristol Myers Squibb | Research and development revenue            
Research And Development Collaboration Agreements [Line Items]            
Revenue from collaborative arrangement       52,600 17,200  
Bristol Myers Squibb Collaboration Agreement | License Agreement Terms, Target Completion | Bristol Myers Squibb | Research and development revenue            
Research And Development Collaboration Agreements [Line Items]            
Revenue from collaborative arrangement     $ 25,800      
Takeda Multi Target Agreement | License Agreement Terms [Member] | Takeda Pharmaceuticals Inc | Research and development revenue            
Research And Development Collaboration Agreements [Line Items]            
Revenue from collaborative arrangement       0 2,600  
Deferred revenue       0 0 0
CPRIT Agreement | Additional Funding Agreement Terms | Cancer Prevention and Research Institute of Texas | Grant            
Research And Development Collaboration Agreements [Line Items]            
Revenue from collaborative arrangement           14,100
Deferred revenue, current       0 200 0
Product development grant awarded   $ 15,200        
Reimbursement amounts submitted in excess of amounts received are recorded as receivables       4,700 0  
Grants revenue receivable       $ 300 $ 0 $ 300